QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nasdaq-cancels-delisting-hearing-for-apollomics-confirms-compliance-with-continued-listing-standards

Apollomics Inc. (NASDAQ:APLM) ("Apollomics" or the "Company"), a California based late-stage clinical biopharma...

Core News & Articles

The Nasdaq Stock Market® (NASDAQ:NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (NASDAQ:AP...

 apollomics-fy24-eps-5280-up-from-23199-yoy

Apollomics (NASDAQ:APLM) reported quarterly losses of $(52.80) per share. This is a 77.24 percent increase over losses of $(231...

 apollomics-and-launxp-announce-development-and-commercialization-agreement-for-vebreltinib-apollomics-to-receive-upfront-payments-of-10m-and-is-eligible-for-pre-commercial-milestones-up-to-50m-and-royalties-on-net-product-sales

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asi...

 apollomics-regains-compliance-with-nasdaqs-minimum-bid-price-requirement

Apollomics Inc. (NASDAQ:APLM) (the "Company"), a clinical-stage biopharmaceutical company developing medicines to addre...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION